BGB-3619

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameBGB-3619

Drug Alias NameBRD4 inhibitor (BeiGene)target-4 for solid/hematological cancers (BeiGene)Bromodomain-containing protein 4 inhibitor (BeiGene)BGB-3619

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBromodomain-containing protein 3 inhibitorsBromodomain and extra terminal domain protein inhibitorsBromodomain-containing protein 2 inhibitors +[4]

TargetsBromodomain-containing protein 3Bromodomain-containing protein 2Bromodomain-containing protein 4 +[4]

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesBeOne Medicines (Beijing) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBeOne Medicines (Beijing) Co Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A